Anticancer
Mar 12, 2012 at 15:12 | Source: Moneycontrol.com
May 04, 2011 at 14:10 | Source: Moneycontrol.com
Nov 11, 2010 at 18:43 | Source: CNBC-TV18
Jun 11, 2010 at 10:23 | Source: Moneycontrol.com
News across the web »
May 27, 2012 at 18:16 | Source: DNA India
May 25, 2012 at 17:52 | Source: DNA India
May 19, 2012 at 05:31 | Source: Economic Times
May 19, 2012 at 02:01 | Source: Business Standard
May 15, 2012 at 06:07 | Source: Economic Times
Interact & exchange stock tips & market info »
Related News »
Saffron extract, a natural product, has been shown to induce apoptosis in several tumor cell lines. Nevertheless, the p53-dependency of saffron's mechanism of action in colon cancer remains unexplored. Methods: In order to examine saffron's anti ...
May 28, 2012 at 17:12 | Source: 7thspace.com
Significantly higher levels of TNF-related apoptosis-inducing ligand protein were found in colostrum and breast milk than in serum. The ability of breast milk to deliver tumor resistance may be associated with the level of TRAIL in it—a level ...
May 16, 2012 at 23:59 | Source: ModernMedicine
A group of plant scientists at the University of Missouri have discovered a new, inexpensive approach to extracting an powerful anticancer chemical from soybeans. The incidence of a number of common cancers (breast, colorectal, prostate, bladder ...
May 23, 2012 at 04:39 | Source: Gizmag
The site, anticancerlifestyle.org, will be a place for alumni of the center's AntiCancer Lifestyle classes to stay in touch and for potential students to get on a waiting list for the next 12-week session. The classes feature information about how diet ...
May 26, 2012 at 04:42 | Source: Concord Monitor
Piramal Healthcare Limited announced that Phase I clinical trial data for its investigational new drug candidate P1446A-05 will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5 ...
May 22, 2012 at 06:56 | Source: equitybulls.com
ImmunoGen, Inc. (NASDAQ: IMGN - News), a biotechnology company that develops targeted antibody-based anticancer products, today announced that there will be four presentations at the upcoming 2012 American College of Clinical Oncology (ASCO ...
May 28, 2012 at 07:32 | Source: Yahoo Finance
Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today ...
May 17, 2012 at 06:12 | Source: PR Newswire
Partners Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals’ anticancer drug Nexavar® (sorafenib) failed to meet its primary endpoint in a Phase III study in patients with advanced non-small cell lung cancer (NSCLC). The 703-patient MISSION study ...
May 23, 2012 at 14:04 | Source: Genetic Engineering News
Utilizing their significant research and operational capabilities, The National Cancer Center and Daiichi Sankyo share a single mission of providing superior anticancer agents to patients as fast as possible. This agreement strengthens ...
May 22, 2012 at 13:51 | Source: TMCnet
Piramal Healthcare has successfully completed the phase I clinical trial of orally acting anticancer compound P1446A-05 and now planning to present phase I clinical trial data for its investigational new drug candidate at the annual meeting of the American ...
May 22, 2012 at 07:17 | Source: pharmabiz.com